We are pleased to announce our joint effort with Boehringer Ingelheim Pharmaceuticals, Inc, a leading research-driven biopharmaceutical company, to launch a program supporting at-home testing and educational information for patients within the US at risk of chronic kidney disease (CKD). Through this collaboration we will work with select partners to help at-risk, previously untested patients use the Minuteful Kidney test kit at the time and place of their choosing. Our aim is to engage more people in their kidney health to achieve earlier identification of CKD.
Early screening and diagnosis is critical in delaying CKD progression, and may help reduce the potential for serious complications down the road. By collaborating with Healthy.io, the ultimate goal is to increase testing for CKD so that those impacted can be evaluated for appropriate care management.
CKD is often referred to as a “silent killer” due to its lack of symptoms in the early stages. While one in three Americans are at risk, most don’t know they have it until it progresses to end-stage renal disease (ESRD), eventually requiring dialysis and/or a kidney transplant. People at risk, including those with diabetes and hypertension, should complete an annual ACR test, yet 80% do not for various reasons. By making Minuteful Kidney available to patients, we can help boost test completion rates, identify CKD early, and engage patients in their care plan.
Minuteful Kidney is a catalyst to increase ACR testing at scale and promote early detection of CKD. Increasing test adherence rates across all demographics and socio-economic groups leads to earlier detection of CKD and provides a path to care for those who need it. This is a true win-win--better health outcomes for patients, as well as reduced costs for payers and providers.
Learn more about how our program with Boehringer Ingelheim can improve test completion rates and help achieve the early identification of CKD here.
